このエントリーをはてなブックマークに追加
ID 67012
フルテキストURL
fulltext.pdf 1.55 MB
著者
Matsuura, Hiroaki Department of Respiratory Medicine, Okayama University Hospital
Higo, Hisao Department of Respiratory Medicine, Okayama University Hospital
Kuribayashi, Tadahiro Department of Respiratory Medicine, Okayama University Hospital
Tamaoki, Akihiko Okayama Health Foundation Hospital, Okayama Health Foundation
Nakasuka, Takamasa Department of Respiratory Medicine, Okayama University Hospital
Uno, Mari Department of Respiratory Medicine, Okayama University Hospital
Makimoto, Go Department of Respiratory Medicine, Okayama University Hospital
Ninomiya, Kiichiro Department of Respiratory Medicine, Okayama University Hospital Kaken ID
Fujii, Masanori Department of Respiratory Medicine, Okayama University Hospital
Rai, Kammei Department of Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki Department of Respiratory Medicine, Okayama University Hospital Kaken ID publons
Hotta, Katsuyuki Department of Respiratory Medicine, Okayama University Hospital Kaken ID publons researchmap
Miyahara, Nobuaki Department of Respiratory Medicine, Okayama University Hospital Kaken ID publons researchmap
Tabata, Masahiro Department of Respiratory Medicine, Okayama University Hospital Kaken ID researchmap
Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
Kiura, Katsuyuki Department of Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Ohashi, Kadoaki Department of Respiratory Medicine, Okayama University Hospital ORCID Kaken ID researchmap
抄録
The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.
キーワード
case report
EGFR-mutated lung cancer
osimertinib
pulmonary tuberculosis
rifampicin
発行日
2024-05-02
出版物タイトル
Thoracic Cancer
15巻
17号
出版者
Wiley
開始ページ
1390
終了ページ
1394
ISSN
1759-7706
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2024 The Authors.
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1111/1759-7714.15324
ライセンス
https://creativecommons.org/licenses/by/4.0/
Citation
Matsuura H, Higo H, Kuribayashi T, Tamaoki A, Nakasuka T, Uno M, et al. Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report. Thorac Cancer. 2024; 15(17): 1390–1394. https://doi.org/10.1111/1759-7714.15324